News | June 05, 2009

Roche, SeqWright Collaborate to Explain Genetic Causes of Heart Disease

June 5, 2009 - Utilizing next generation sequencing and the latest advancements in sequence capture, genomic and molecular biology services company SeqWright, is collaborating with Roche Applied Science and the University of Miami Miller School of Medicine to identify possible genetic variants associated with dilated cardiomyopathy, a disease of heart muscle.

In this collaboration SeqWright used NimbleGen Sequence Capture Human Exome Arrays to enrich more than 180,000 exons from DNA samples from individuals affected with dilated cardiomyopathy. Using the Genome Sequencer FLX, a technology of 454 Life Sciences, SeqWright is sequencing the enriched exons to detect genetic variants within these samples, including single nucleotide polymorphisms (SNP’s) and insertions and deletions. The complete solution from Roche allows targeted resequencing of all of the coding exons, called the human exome, representing the portion of the human genome that is transcribed and translated into the myriad of proteins that function within all cells in the human body.

Sequencing the entire coding portion of the human genome has not been feasible until recent advancements in next generation genomic tools, and by being able to efficiently characterize the entire human exome, researchers can accelerate their research by taking the ‘candidate gene’ approach to a completely new level, SeqWright said.

“Dilated cardiomyopathy is a leading cause of heart failure that carries a high mortality rate,” said Nadine Norton, Ph.D., a research assistant professor from the University of Miami Miller School of Medicine. “We know that familial dilated cardiomyopathy (FDC) can be explained by mutations in more than 20 autosomal and two X-linked genes, yet mutations in these genes account for only one-third of the cause. By using an experimental strategy that employs the sequencing of all coding regions within the human genome, we hope to identify other mutations in other genes that cause this terrible disease.”

This work is part of an ongoing 15-year study of familial dilated cardiomyopathy brought to the Miller School of Medicine in 2007 by Ray Hershberger, M.D., professor of medicine and associate chief of the cardiovascular division.

Funding to Dr. Hershberger for this project has been provided by the NIH’s National Heart Lung and Blood Institute and the Florida Heart Research Foundation.

More information is available at www.fdc.to, www.nimblegen.com, www.roche.com, www.seqwright.com

Related Content

The Corus CAD genetic test is a simple, noninvasive blood test that is clinically available for the assessment of obstructive coronary artery disease.

The Corus CAD gene expression test is a simple, noninvasive blood test that is available to assess a patient’s current likelihood of having obstructive coronary artery disease (CAD).

 

Feature | Genetic Testing | December 13, 2017 | Andrew Waxler, M.D., FACC
The diagnosis and management of cardiovascular disease has long followed a familiar approach.
genetic testing, sudden cardiac death of teen, Mayo Clinic Proceedings
News | Genetic Testing | November 09, 2016
The recent, sudden death of a 13-year-old boy resulted in more than 20 relatives being incorrectly diagnosed as having...
News | Genetic Testing | July 26, 2016
July 26, 2016 — A new study has identified a genetic error that weakens the aorta, placing patients with this and sim
Feature | Genetic Testing | December 22, 2015 | Kevin P. Greene, M.D.
Statins are lifesaving medications — they have been shown to greatly reduce heart attack and other related events by
Invitae Corp., cardiovascular test panels, genetic testing, expands offerings
Technology | Genetic Testing | October 08, 2015
Invitae Corp., a genetic information company, announced the expansion of its cardiology offering, including more than...
genomic testing, NGS, FDA, Precision Medicine Initiative, PMI, workshops
Feature | Genetic Testing | September 21, 2015
The U.S. Food and Drug Administration (FDA) will hold a pair of public workshops in November to explain ongoing efforts...
Overlay Init